PFE · News · 20260817N
Product / Drug Pipeline Progress
PFIZER INC · 2026-08-17 · Importance 31 · Surprise 42 · In source text
Pfizer’s Lyme disease vaccine candidate, developed with Valneva, reported 73% efficacy and has received EMA validation. The candidate could generate royalty and milestone income for Valneva if approved and successfully commercialized, indicating potential future commercialization value for Pfizer’s vaccine portfolio. The report characterizes the program as a key anchor of Valneva’s transition toward a royalty- and milestone-based model.
Key facts
- Pfizer's Lyme vaccine candidate is reported to have 73% efficacy and EMA validation, according to the article about Valneva's partnership with Pfizer. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Pfizer's Lyme vaccine candidate is reported to have 73% efficacy and EMA validation, according to the article about Valneva's partnership… |